Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25159743 | 0.88 | CA1 (0.47) | CA1CA2ENPP1NCF1USP30 | |
| SCHEMBL18559454 | 0.80 | CA12 (0.39) | CA1CA2CA12CA7CA14 | |
| SCHEMBL799013 | 0.80 | CA12 (0.39) | CA12CA7CA14POLBHTR2A | |
| SCHEMBL1646299 | 0.78 | — | — | |
| SCHEMBL12801178 | 0.77 | HTR2A (0.38) | CA12CA7CA14NCF1POLB | |
| SCHEMBL18912347 | 0.76 | CA1 (0.53) | CA1CA2ENPP1CA12CA7 | |
| Hydrochloric Acid SCHEMBL29262605 | 0.76 | — | — | |
| SCHEMBL2743246 | 0.75 | GRIA2 (0.38) | — | |
| SCHEMBL2743275 | 0.75 | CA12 (0.34) | CA1CA12CA7CA14NCF1 | |
| SCHEMBL1644220 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458160-B2 | Peripherally restricted diphenyl purine derivatives | RESEARCH TRIANGLE INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| CN-102307872-B | BCL-2-selectively apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE 公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20160046630-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | RES TRIANGLE INST (US) | 2016-02-18 | — | — | US | disclosed |
| US-9187480-B2 | Peripherally restricted diphenyl purine derivatives | RESEARCH TRIANGLE INSTITUTE (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150031689-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-29 | — | — | US | disclosed |
| US-8552031-B2 | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8552031-B2 | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| CN-102816170-A | Novel macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE INC | 2012-12-12 | — | — | CN | disclosed |
| US-20090281317-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281317-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| CN-101263156-A | Novel macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE INC (US) | 2008-09-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031689-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | CNR1, CNR2, P2RY1 | CA1 4716/4885CA2 4465/4885ENPP1 212/4885 |
| US-20160046630-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | CNR1, CNR2, P2RY1 | CA1 4716/4885CA2 4465/4885ENPP1 212/4885 |
| US-20090281317-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | MPL, TEK, THPO | CA1 4469/4885CA2 3848/4885ENPP1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.